Varicella Treatment and Prevention

Post-Exposure Prophylaxis

• The Centers for Disease Control and Prevention recommends Varicella-Zoster Immune Globulin (VZIG) administration within 96 hours of exposure to susceptible high-risk individuals, including pregnant women, immunocompromised patients, and premature infants less than 28 weeks gestation or less than 1,000 g, to prevent varicella [1, 2]
• VZIG prevents maternal complications rather than fetal infection in pregnant women and does not prevent congenital varicella syndrome [1, 2]
• Neonates born to mothers with varicella from 5 days before to 2 days after delivery should receive VZIG regardless of whether the mother received it [1, 2]
• The American Academy of Pediatrics suggests that premature infants born at less than 28 weeks gestation or weighing less than 1,000 g should receive VZIG after exposure regardless of maternal immunity status [1, 2]
• Healthy full-term infants exposed postnatally do not require VZIG even if mothers lack varicella history [1, 2]
• Patients receiving VZIG should be observed for 28 days after exposure as it may prolong the incubation period [1, 2]

Vaccination

• The American Academy of Pediatrics recommends that varicella vaccine is contraindicated during active infection but should be considered after recovery for those who remain susceptible [3]

Treatment of Varicella in Adults

Special Considerations

• Immunocompromised patients should receive antiviral therapy regardless of when treatment is initiated due to higher risk of disseminated infection, as recommended by the guideline society 4
• Acyclovir is FDA Pregnancy Category B with no increased birth defects documented in 596 first-trimester exposures, according to the guideline society 4

Post-Exposure Prophylaxis

• Varicella-zoster immune globulin (VZIG) is strongly preferred for pregnant women exposed to varicella, administered within 96 hours of exposure, as recommended by the Centers for Disease Control and Prevention 5 and the guideline society 4
• For susceptible adults exposed to varicella, VZIG within 96 hours of exposure is first-line prophylaxis, as recommended by the Centers for Disease Control and Prevention 5 and the guideline society 4
• If VZIG is unavailable or >96 hours post-exposure, acyclovir 20 mg/kg (maximum 800 mg) four times daily for 5-7 days, initiated 7-10 days after exposure, is an alternative, according to the guideline society 4

Differential Diagnosis

• Do not confuse varicella (chickenpox) treatment with herpes zoster (shingles) treatment, which has a 72-hour window rather than 24-hour window for efficacy, as noted by the guideline society 6

Management of Chickenpox

Initial Assessment and Risk Stratification

• Immunocompromised patients require immediate IV acyclovir regardless of when they present, as stated by the Gut guideline society 7

Symptomatic Management for All Patients

• Antipyretics for fever should be used, avoiding aspirin due to Reye's syndrome risk in children, as recommended by the Gut guideline society 7

Infection Control Measures

• Airborne precautions and contact precautions for all hospitalized patients with varicella are critical, as recommended by the Centers for Disease Control and Prevention (CDC) guideline society 8
• Patients are infectious up to 2 days before rash onset through lesion crusting, according to the CDC guideline society 8
• Maintain precautions until all lesions are dry and crusted, as stated by the CDC guideline society 8
• Patients are infectious up to 2 days before rash onset through lesion crusting, as recommended by the CDC guideline society 9

Post-Exposure Management of Contacts

• Varicella vaccination within 3-5 days of exposure may modify disease if infection has not yet occurred, as recommended by the CDC guideline society 9
• Monitor exposed susceptible persons daily for fever, skin lesions, and systemic symptoms during days 10-21 after exposure, as stated by the CDC guideline society 9
• Acyclovir prophylaxis starting 7-10 days post-exposure may be considered for high-risk susceptible contacts, as recommended by the Gut guideline society 7

Vaccination Considerations

• Live varicella vaccine is contraindicated during active infection and in patients receiving immunosuppressive therapy, as stated by the Gut guideline society 7
• Immunomodulators should be withheld for 4 weeks after live vaccine administration, as recommended by the Gut guideline society 7
• Live vaccines should be avoided for at least 3 months after discontinuing immunosuppressive therapies, as stated by the Gut guideline society 7

Management of Vaccinated Individuals Exposed to Chickenpox

Risk Stratification Based on Vaccination Status

• The Centers for Disease Control and Prevention recommends that vaccinated individuals exposed to varicella receive a second dose of vaccine within 3-5 days of exposure if they have only received one dose, while those who have received two doses require monitoring only—no additional intervention is needed 10, 11
• No postexposure prophylaxis is required for individuals who have received 2 doses of varicella vaccine, according to the Centers for Disease Control and Prevention 10
• The American Academy of Pediatrics recommends monitoring daily during days 8-21 after exposure for fever, skin lesions, and systemic symptoms suggestive of varicella in two-dose vaccine recipients 10
• Individuals who have received 2 doses of varicella vaccine should be excluded from work/school immediately if any symptoms develop, as recommended by the Centers for Disease Control and Prevention 10, 11
• The Centers for Disease Control and Prevention recommends administering the second dose within 3-5 days after exposure to rash for one-dose vaccine recipients, provided at least 4 weeks have elapsed since the first dose 10, 11
• If the second dose is not given or is given >5 days after exposure, one-dose vaccine recipients should be excluded from work/school for days 8-21 after exposure, according to the Centers for Disease Control and Prevention 10, 11

Special Populations Requiring Alternative Prophylaxis

• The Centers for Disease Control and Prevention recommends administering Varicella-Zoster Immune Globulin (VZIG) within 96 hours of exposure for high-risk individuals who cannot receive vaccine, such as pregnant women, immunocompromised patients, and premature infants 10, 11
• VZIG may prolong the incubation period by one week, extending the monitoring/exclusion period from 21 to 28 days, as recommended by the Centers for Disease Control and Prevention 10, 11

Critical Pitfalls to Avoid

• Birth before 1980 is NOT considered evidence of immunity for healthcare personnel due to the risk of nosocomial transmission to high-risk patients, according to the Centers for Disease Control and Prevention 12
• Routine serologic testing after 2 doses of vaccine is not recommended for management of vaccinated individuals, as available commercial assays are not sensitive enough to detect antibody after vaccination in all instances, as stated by the Centers for Disease Control and Prevention 12

Healthcare Setting Considerations

• Healthcare institutions should ensure all personnel have evidence of immunity to varicella through documentation of 2 doses of vaccine, as recommended by the Centers for Disease Control and Prevention 12
• Serologic screening before vaccination of personnel with negative or uncertain history is likely cost-effective, according to the Centers for Disease Control and Prevention 12

Management of Active Varicella in Adults

Vaccination Recommendations

• The CDC advises that varicella vaccine should not be administered to an adult with confirmed active chickenpox because vaccination during active infection is contraindicated. 13
• After recovery from active varicella, vaccination should be deferred for at least 5 months to ensure adequate immune response. 14
• Individuals who have recovered from natural varicella infection do not require subsequent vaccination, as they acquire natural immunity. 13
• If varicella‑zoster immune globulin (VZIG) has been given, the CDC recommends delaying varicella vaccination for 5 months after VZIG administration. 14

Post‑Exposure Prophylaxis (PEP)

• VZIG is indicated only for susceptible (non‑immune) persons within 96 hours of exposure to prevent disease; it is not appropriate for patients who already have active infection. 14
• The varicella vaccine is intended for pre‑exposure prevention or post‑exposure prophylaxis when given 3–5 days after exposure to a susceptible individual; it is not a treatment for active disease. 13
• In the scenario of a mother with a confirmed active rash, both VZIG and varicella vaccination are inappropriate interventions. [13][15]14

Infection Control

• The CDC recommends implementing airborne and contact precautions for individuals with active varicella; they are infectious from 2 days before rash onset until all lesions are completely crusted and dry. Isolation should be maintained until this point. 16

Household Contact Management

• Assess the immunity status of all household members (e.g., partner, children) to identify susceptible contacts. 13
• Susceptible household contacts should receive varicella vaccine within 3–5 days of exposure to modify disease severity (guideline recommendation, not directly cited).
• High‑risk susceptible contacts—such as immunocompromised individuals, pregnant women, or premature infants—should be given VZIG within 96 hours of exposure to prevent severe disease. 14

Clinical Distinction

• The CDC emphasizes that post‑exposure prophylaxis must be administered before disease onset; once the characteristic rash appears, management shifts to supportive care and monitoring, not prophylactic interventions. [13][14]

Management of Active Varicella in Pregnant Women and Household Contacts

Therapeutic Role of VZIG in the Infected Mother

• VZIG provides passive antibodies to prevent or attenuate varicella infection but cannot reverse disease once the characteristic rash is present, therefore it has no therapeutic role for a mother with confirmed active chickenpox. [CDC MMWR Recommendations 2007] 17, 18

Assessment of Immunity in Household Members

• Immunity in contacts is confirmed by documented two‑dose varicella vaccination, laboratory‑confirmed IgG positivity, or a health‑care‑provider‑verified history of varicella or herpes zoster. [American Academy of Pediatrics 2007] 19

Risk of Transmission to Susceptible Household Contacts

• Approximately 85 % (range 65‑100 %) of susceptible household members develop varicella after exposure to an infected individual. [CDC MMWR Recommendations 2007] 18

Post‑Exposure Prophylaxis for High‑Risk Susceptible Contacts

• High‑risk individuals (immunocompromised persons, pregnant women, premature infants) who are susceptible should receive VZIG within 96 hours of exposure to prevent severe disease. [CDC MMWR Recommendations 2007] 17, 18
• In pregnant women without prior immunity who are exposed, VZIG reduces the infection rate from >70 % to ≈30 % and markedly lowers severe outcomes such as pneumonia. [CDC MMWR Recommendations 2007] 18

Timing of Prophylactic Interventions for Household Contacts

• Prompt assessment of household contacts is essential because the effectiveness window for VZIG is ≤96 hours and for post‑exposure vaccination is 3‑5 days after exposure; delays may render prophylaxis ineffective. [CDC MMWR Recommendations 2007] 17